Business
INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH
Company will host an investor conference call today at 11:00 AM ET LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the
About this update from Inmune Bio Inc.
[{"type":"text","content":"Company will host an investor conference call today at 11:00 AM ET\nLA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the fourth quarter and full year ended December 31, 2019 and is providing a business update.\n The Company will hold a conference call today at 11AM Eastern (U.S.) time. To participate in the live conference call, please dial 1-877-407-2988 five minutes prior to the scheduled conference call time and ask for the, “INmune Bio Conference Call.” International callers should dial 1-201-389-0923. Participants can also use this link for instant telephone access to the event. 2019 and Recent Corporate Highlights on the DN-TNF Platform and NK Priming Platform: Closed an initial public offering (“IPO”) and commenced trading on The Nasdaq Capital Market.Added two new independent members to the board of directors; Ed Baracchini former chief business officer of Xencor, Inc. who has negotiated many transactions with pharmaceutical and biotechnology companies and; Marcia Allen, a fortune 500 executive with vast accounting and finance experience. DN-TNF Platform Highlights: Successfully reported Phase I clinical data that INB03™ demonstrates safety and efficacy in cancer patients and has announced that the Phase II program will target trastuzumab resistance in women with HER2+ breast cancer using INB03™ as part of combination therapy.Awarded a $1,000,000 grant from The Alzheimer’s Association allowing INMB to initiate a Phase 1 clinical trial using XPro1595 to treat patients with Alzheimer’s Disease.Awarded a $500,000 grant from The ALS Association to complete IND enabling pre-clinical studies with XPro1595 as a therapy for ALS.Initiated a program in NASH with LIVNate™ the third drug development program from the DN-TNF platform, joining DN-TNF platform drug candidates INB03™ and XPro1595.XPro1595 had 9 articles published in peer review journals by academic collaborators and INB03 was one of 85 abstracts (out of 885) to be given as an oral presentation at SITC2019.United States Patent and Trademark Office (USPTO) has issued Patent No. 15/776,061 on January 28, 2020, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMO...